FDA Removing Pharmaceutical Representatives From Advisory Panels
The agency’s new commissioner announced the move.
Dr. Marty Makary, then the nominee to lead the Food and Drug Administration, testifies during a confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions on Capitol Hill in Washington on March 6, 2025. Madalina Vasiliu/The Epoch Times
The Food and Drug Administration (FDA) is removing pharmaceutical company representatives from advisory committees in a bid to limit industry influence.
Dr. Marty Makary, the FDA’s new commissioner, issued a directive that eliminates the role of pharmaceutical representative.
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
